Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis and melanoma.

J P Dutcher1

  • 1New York Medical College, Our Lady of Mercy Cancer Center, 600 East 233rd Street, Bronx, NY 10466, USA. jpd4401@aol.com

Current Oncology Reports
|June 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

Journal for immunotherapy of cancer·2019
Same author

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Characterization of bone metastases in patients with renal cell cancer.

BJU international·2004
Same author

Accelerated and blastic phase of chronic myeloid leukemia.

Current treatment options in oncology·2002
Same author

Phase I study of recombinant human CD40 ligand in cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

Blood·2001
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Angiogenesis, the formation of new blood vessels, fuels tumor growth and metastasis. Targeting this process with new anticancer drugs is a key focus in cancer research and development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Angiogenesis is crucial for tumor growth, survival, and metastasis.
  • Growth factors like VEGF stimulate tumor angiogenesis.
  • Neo-angiogenesis is particularly important in melanoma proliferation and spread.

Purpose of the Study:

  • To explore the role of angiogenesis in tumor progression.
  • To evaluate biologic markers of angiogenesis for prognostic and therapeutic insights.
  • To highlight the development of anti-angiogenesis therapies for cancer treatment.

Main Methods:

  • Review of scientific literature on angiogenesis and cancer.
  • Analysis of the role of growth factors in tumor vascularization.
  • Evaluation of biologic markers for predicting tumor behavior and treatment response.

Related Experiment Videos

Main Results:

  • Angiogenesis is stimulated by intrinsic growth factors.
  • Neo-angiogenesis is critical for melanoma proliferation and metastasis.
  • Angiogenesis markers may predict prognosis and targeted therapy susceptibility.

Conclusions:

  • Interruption of tumor angiogenesis is a major strategy in anticancer drug development.
  • Numerous anti-angiogenesis agents are in preclinical and clinical development.
  • Targeting angiogenesis holds significant promise for future cancer therapies.